Literature DB >> 28580642

Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review.

C A Riemer1, R A El-Azhary2, K L Wu3, J J Strand2, J S Lehman2.   

Abstract

Calciphylaxis is associated with significant morbidity and mortality. Palliative care (PC) is a subspecialty that treats the pain and stress of serious illness. To assess whether the role of quality of life (QoL) indices, patient-reported outcome measures and PC have been studied in patients with calciphylaxis, we performed a systematic literature review. Several databases were searched from inception to October 2016 according to modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. We searched for papers on calciphylaxis that mentioned the symptoms and supportive needs of patients, QoL or outcome measures to report symptom severity, and the involvement of PC. Twelve papers met the inclusion criteria. Reported patient symptoms included pain, skin lesion resolution and pruritus, with the first being the most frequently reported. Four papers measured pain using a previously verified patient-reported outcome measure, including the Visual Analogue Scale. One paper used a verified QoL measure, the Dermatology Quality of Life Index. No tool was used consistently. Eight papers reported the use of hospice care or PC in the treatment of calciphylaxis. No outcome measure was used to prompt PC involvement. Overall, QoL indices, patient-reported outcome measures and PC are underreported in the treatment of calciphylaxis. PC may be a resource to assist in symptom management and adaptive coping strategies for patients from the onset of disease.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 28580642     DOI: 10.1111/bjd.15702

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis.

Authors:  Kabir O Olaniran; Shananssa G Percy; Sophia Zhao; Chantal Blais; Vicki Jackson; Mihir M Kamdar; Jeremy Goverman; Daniela Kroshinsky; Jennifer S Temel; Sagar U Nigwekar; Nwamaka D Eneanya
Journal:  J Pain Symptom Manage       Date:  2018-11-03       Impact factor: 3.612

2.  Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.

Authors:  Vincent M Brandenburg; Smeeta Sinha; Jose-Vicente Torregrosa; Rekha Garg; Stephan Miller; Ana-Zeralda Canals; Daun Bahr; Pieter H Joubert; Carolina Salcedo; Kevin J Carroll; Alex Gold; Joan Perelló
Journal:  J Nephrol       Date:  2019-08-10       Impact factor: 3.902

Review 3.  Assessing the compliance of systematic review articles published in leading dermatology journals with the PRISMA statement guidelines: A systematic review.

Authors:  Buket Gundogan; Naeem Dowlut; Shivanchan Rajmohan; Mimi R Borrelli; Mirabel Millip; Christos Iosifidis; Yagazie Z Udeaja; Ginimol Mathew; Alexander Fowler; Riaz Agha
Journal:  JAAD Int       Date:  2020-09-07

4.  Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians.

Authors:  Rajkumar Chinnadurai; Smeeta Sinha; Aoife C Lowney; Mary Miller
Journal:  BMC Nephrol       Date:  2020-09-18       Impact factor: 2.388

5.  The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.

Authors:  Smeeta Sinha; Lisa J Gould; Sagar U Nigwekar; Thomas E Serena; Vincent Brandenburg; Sharon M Moe; George Aronoff; Dinesh K Chatoth; Jeffrey L Hymes; Stephan Miller; Claire Padgett; Kevin J Carroll; Joan Perelló; Alex Gold; Glenn M Chertow
Journal:  Clin Kidney J       Date:  2021-07-06

6.  Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients.

Authors:  Yu-Huan Song; Si-Yang Wang; Jia-Hui Lang; Yue-Fei Xiao; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.